Related Experiment Video

Updated: Jul 16, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in

Mark A Socinski1, Martin Reck2, Luis Paz-Ares3

  • 1AdventHealth Cancer Institute, Orlando, Florida.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|July 14, 2026
PubMed
Abstract

Insights

Ociperlimab plus tislelizumab did not improve overall survival compared to pembrolizumab in advanced non-small cell lung cancer. Survival outcomes were similar across all treatment arms, with well-tolerated safety profiles.

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Novel therapeutic strategies are crucial for improving outcomes in non-small cell lung cancer (NSCLC).
  • Co-inhibition of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitor motif domains (TIGIT) and programmed cell death protein-1 (PD-1) may enhance anti-PD-1 therapy.
  • The AdvanTIG-302 trial investigated ociperlimab plus tislelizumab in first-line advanced NSCLC.

Purpose of the Study:

  • To evaluate the efficacy of ociperlimab plus tislelizumab compared to pembrolizumab in first-line stage III/IV NSCLC with high PD-L1 expression.
  • Primary endpoint was overall survival (OS) in arm A versus arm B.
  • Secondary endpoints included progression-free survival (PFS) and overall response rate (ORR).

Main Methods:

  • Phase 3, randomized trial (AdvanTIG-302) with a 5:5:2 allocation ratio.
  • Patients received ociperlimab plus tislelizumab (Arm A), pembrolizumab (Arm B), or tislelizumab (Arm C).
  • Interim analysis of 662 patients was conducted, with efficacy analyses being descriptive.

Main Results:

  • The interim analysis was terminated due to futility; efficacy data are descriptive.
  • Median OS was comparable across arms: 31.9 months (Arm A), 29.4 months (Arm B), and 27.7 months (Arm C).
  • Median PFS: 14.3 months (A), 10.5 months (B), 16.6 months (C). ORR: 61.0% (A), 48.8% (B), 55.7% (C).

Conclusions:

  • Ociperlimab plus tislelizumab did not demonstrate improved OS compared to pembrolizumab.
  • Overall survival was comparable across all treatment arms.
  • All treatment regimens exhibited well-tolerated safety profiles without new safety signals.
Keywords:
ImmunotherapyNon–small cell lung cancerOciperlimabPhase 3Tislelizumab

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.